Wednesday, September 28, 2016 5:27:27 PM
1. They have a marketable product. I'm really pumped about this prototype but it isn't something they can sell yet.
If you take a look at the 10Q/Ks, the company has no intent on making a marketable product. The intent of the company is to license out the technology. I think this will have a pretty major advantage because they will not have to try to create the infanstructure for hydrogen. Whatever company license out the technology will be able to piggyback off of the hydrogen advances they've already made. I think some major candidates are Power Plug, DuPont, and Airgas.
2. They actually have sales/revenue.
This will come in the form of a licensing agreement as laid out above. With the functioning prototype I think we could see an early access license agreement at any time. If not anything you could probably get a full licensing agreement within a year. However, due to the company's debt I don't think we're going to see a straight buy out for a few years down the road.
3. It gets listed on one of the bigger exchanges.
I think that's about 2 to 3 years away. But I think we can hit a $1+ within a year.
Recent HYSR News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 09:31:40 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/02/2024 05:15:09 AM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 01/25/2024 09:40:59 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/24/2024 09:32:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 08:28:16 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2023 09:03:04 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/29/2023 08:33:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2023 08:13:34 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM